Skye Bioscience (SKYE) Amortization of Deferred Charges (2015 - 2026)
Skye Bioscience (SKYE) posted quarterly Amortization of Deferred Charges of $170367.0 for Q1 2026, up 129.25% quarter-over-quarter from -$582550.0 in Q4 2024.
Skye Bioscience (SKYE) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Amortization of Deferred Charges for 9 consecutive years, with $170367.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $170367.0; the TTM figure through Mar 2026 stood at $170367.0 (up 129.75% YoY), while the FY2024 annual figure was $16456.0, down 95.01% from the prior year.
- Amortization of Deferred Charges rose to $170367.0 in Q1 2026 per SKYE's latest filing, from -$582550.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $488262.0 in Q4 2022 and bottomed at -$582550.0 in Q4 2024.
- Historically, Amortization of Deferred Charges has averaged $73531.8 across 4 years, with a median of $6874.0 in 2024.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges jumped 39298.47% — and 2024, when it plunged 278.11%.
- Skye Bioscience's Amortization of Deferred Charges stood at $488262.0 in 2022, then sank by 33.01% to $327077.0 in 2023, then slumped by 278.11% to -$582550.0 in 2024, then soared by 129.25% to $170367.0 in 2026.
- Business Quant data shows SKYE's Amortization of Deferred Charges at $170367.0 in Q1 2026, -$582550.0 in Q4 2024, and $3063.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Skye Bioscience | 10.86 Mn | 10.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 170,367.00 |
| Mar 31, 2026 | 170,367.00 |
| Dec 31, 2024 | -582,550.00 |
| Dec 31, 2024 | -582,550.00 |
| Sep 30, 2024 | 3,063.00 |
| Sep 30, 2024 | 3,063.00 |
| Jun 30, 2024 | 6,874.00 |
| Jun 30, 2024 | 6,874.00 |
| Mar 31, 2024 | 237,205.00 |
| Mar 31, 2024 | 237,205.00 |
| Dec 31, 2023 | 327,077.00 |
| Dec 31, 2023 | 327,077.00 |
| Sep 30, 2023 | 2,813.00 |
| Sep 30, 2023 | 2,813.00 |
| Dec 31, 2022 | 488,262.00 |
| Dec 31, 2022 | 488,262.00 |
| Sep 30, 2022 | 459.00 |
| Sep 30, 2022 | 459.00 |
| Jun 30, 2022 | 444.00 |
| Jun 30, 2022 | 444.00 |